Erratum To: Postmenopausal Estrogen Monotherapy–associated Breast Cancer Risk Is Modified by CYP17A1_-34_T>C Polymorphism

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-010-0880-5
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Springer Science and Business Media LLC

Related search

Serum Estrogen Receptor Bioactivity and Breast Cancer Risk Among Postmenopausal Women

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2013English

The VEGF -634g>c Promoter Polymorphism Is Associated With Risk of Gastric Cancer

BMC Gastroenterology
MedicineGastroenterology
2009English

Breast Cancer Risk by Breast Density, Menopause, and Postmenopausal Hormone Therapy Use

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Angiotensin Converting Enzyme Insertion/Deletion Polymorphism Is Associated With Breast Cancer Risk: A Meta-Analysis

Asian Pacific Journal of Cancer Prevention
2018English

Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women

Yearbook of Anesthesiology and Pain Management
2010English

Prediagnostic Leptin, Adiponectin, C-Reactive Protein, and the Risk of Postmenopausal Breast Cancer

Cancer Prevention Research
MedicineCancer ResearchOncology
2013English

Intake of Specific Fruits and Vegetables in Relation to Risk of Estrogen Receptor-Negative Breast Cancer Among Postmenopausal Women

Journal of the Academy of Nutrition and Dietetics
MedicineNutritionFood ScienceDietetics
2013English

Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women

Yearbook of Oncology
2010English

The Association Between Estrogen Receptor Alpha Gene Rs746432 Polymorphism and the Risk of Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy